Document Detail


Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.
MedLine Citation:
PMID:  9153489     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Interferon beta-1a and -1b reduce the frequency and severity of clinical exacerbations, and reduce both T2-weighted and contrast-enhanced MRI activity in patients with multiple sclerosis (MS). Several recent reports suggest that at the initiation of treatment there may be transient worsening of symptoms associated with the induction of interferon gamma-secreting cells. We studied eight MS patients with weekly brain MRI's after starting interferon beta treatment, and found immediate reduction in the number of contrast-enhancing lesions. Several patients did experience recurrence of previous symptoms without concomitant opening of the blood brain barrier on contrast-enhanced MRI. These data suggest that the symptoms described after the initiation of interferon beta are not associated with new disease activity, but rather may be related to preexisting lesions. This has implications for both understanding the immunopathogenesis of the disease and for its treatment.
Authors:
P A Calabresi; L A Stone; C N Bash; J A Frank; H F McFarland
Related Documents :
1029009 - Pattern visual evoked potentials in the diagnosis of multiple sclerosis and other disor...
18676439 - Perivascular spaces--mri marker of inflammatory activity in the brain?
16434649 - Virtual reality cues for improvement of gait in patients with multiple sclerosis.
1251679 - Circulating ige, allergy and multiple sclerosis. serum levels of ige, other immunoglobu...
6758679 - Correlation of isotopic cisternographic patterns in multiple sclerosis with csf igg val...
1839869 - An intraoral prosthesis to control drooling in a patient with amyotrophic lateral scler...
8108539 - Aspiration in acute stroke: a clinical study with videofluoroscopy.
6787559 - Echocardiographic mitral valve deformity in the mucopolysaccharidoses.
21940699 - Clinical associations of occipital intermittent rhythmic delta activity.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurology     Volume:  48     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-06-11     Completed Date:  1997-06-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1446-8     Citation Subset:  AIM; IM    
Affiliation:
Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Brain / pathology
Female
Humans
Image Enhancement
Interferon-beta / adverse effects,  therapeutic use*
Magnetic Resonance Imaging*
Male
Multiple Sclerosis / diagnosis*,  therapy*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cramps and minimal EMG abnormalities as preclinical manifestations of spinal muscular atrophy patien...
Next Document:  Traumatic brainstem deafness with normal brainstem auditory evoked potentials.